Windlas Biotech shares drop 6% after FSDA notice
after close1 source ↓written by the desknot a recommendation
- to ₹803 following
- 6%
- this fiscal
- ₹55.21 cr
- Despite
- 19% YoY revenue increase
- industry average
- 29.6
Windlas Biotech's shares fell 6% to ₹803 following an FSDA show-cause notice, temporarily suspending its codeine-based cough syrup manufacturing. This segment contributed ₹55.21 cr this fiscal. Despite a 19% YoY revenue increase, regulatory uncertainty is impacting investor sentiment, with the stock trading at a PE of 25.4 compared to the industry average of 29.6.
Not investment advice. For informational purposes only.